Insilico Studies of Tau-protein Kinase

Insilico Studies of Tau-protein Kinase

Ranganadha R.A.

Department of Biotechnology, VFSTR University, Vadlamudi, Guntur 522213, Andhrapradesh, India

Corresponding Author Email: 
rangaaluri@gmail.com
Page: 
211-214
|
DOI: 
https://doi.org/1018280/ama_b.610406
Received: 
18 September 2018
| |
Accepted: 
26 November 2018
| | Citation

OPEN ACCESS

Abstract: 

One of the most common types of dementia is Alzheimer’s disease and it is related to tangles and plaques in the brain. Memory loss and symptoms like confusion and difficulty with remembering things indicate the onset of the disease. The symptoms are signs given by body to indicate brain cells death. In brain there are 100 billion nerve cells commonly known as neurons. Networks are formed when communication takes place between these nerve cells. Alzheimer’s disease is very much similar to other forms of dementia as with time more and more brain cells die. Tau protein kinase enzyme catalyzes the transferring of the phosphate group to the oxygen side chains of the serine / threonine residues. Tau protein is one of the vital proteins that are present in the central nervous systems it helps to stabilize the neurons and microtubules. One of the main features of Alzheimer’s is abundantly found neurofibrillary lesions that are made from Tau-protein that has been hyperphoshorylated. For stabilizing microtubules Tau-protein interact with tubulin. Auto assemblage of tangles with in the straight filaments and helical fragments takes place due to excessive phosphorylation of tau-protein. Dementia is caused to due malfunctioning of tau-protein that further causes Alzheimer’s disease.

Keywords: 

Alzheimer, tau protein, homology modeling, SWISS MODEL

1. Introduction
2. Methodology
3. Results and Discussion
4. Conclusion
  References

[1] Berchtold NC, Cotman CW. (1998). Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiology of Aging 19(3): 173–189. https://doi.org/10.1016/S0197-4580 (98)00052-9

[2] Brookmeyer R, Gray S, Kawas C. (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 88(9): 1337–1342. https://doi.org/ 10.2105/AJPH.88.9.1337

[3] Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. (2007). Forecasting the global burden of Alzheimer’s disease. Alzheimer's and Dementia 3(3): 186–91. https://doi.org/10.1016/j.jalz.2007.04.381

[4] Waldemar G, Dubois B, Emre M. (2007). Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology 14(1): 1–26. https://doi.org/10.1111/j.1468-1331.2006.01605.x

[5] Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH, Marder K, Albers MW, Stern Y, Devanand DP. (2005). A 10-item smell identification scale related to risk for Alzheimer's disease. Annals of Neurology 58 (1): 155–160. https://doi.org/10.1002/ana.20533

[6] Mölsä PK, Marttila RJ, Rinne UK. (1986). Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurologica Scandinavica 74(2): 103–107. https://doi.org/10.1111/j.1600-0404.1986.tb04634.x 

[7] Mölsä PK, Marttila RJ, Rinne UK. (1995). Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. Acta Neurologica Scandinavica 91(3): 159–164. https://doi.org/10.1111/j.1600-0404.1995.tb00426.x

[8] Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. (2004). The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62(11): 1984–1989. https://doi.org/10.1212/01.WNL.0000129697.01779.0A

[9] Murray J, Schneider J, Banerjee S, Mann A. (1999). EUROCARE: A cross-national study of co-resident spouse careers for people with Alzheimer's disease: II--A qualitative analysis of the experience of care giving. International Journal of Geriatric Psychiatry 14(8): 662–667. https://doi.org/10.1002/(SICI)1099-1166(199908)14:8<662::AID-GPS993>3.0.CO;2-4

[10] Meek PD, McKeithan K, Schumock GT. (1998). Economic considerations in Alzheimer's disease. Pharmacotherapy 18(2): 68–73. https://doi.org/10.1002/j.1875-9114.1998.tb03880.x

[11] Taniguchi T, Kawamata T, Mukai H, Hasegawa H, Isagawa T, Yasuda M, Hashimoto T, Terashima A, Nakai M, Mori H, Ono Y, Tanaka C. (2001). Phosphorylation of tau is regulated by PKN. Journal of Biological Chemistry 276(13): 10025–10031.https://doi.org/10.1074/jbc.M007427200

[12] Benkert P, Biasini M, Schwede T. (2011). Toward the estimation of the absolute quality of individual protein structure models. Bioinformatic 27(3): 343-350. https://doi.org/10.1093/bioinformatics/btq662

[13] Laskowski Roman A, Malcolm W, MacArthur, David SM, Jnaet MT. (1993) PROCHECK: A program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 26(2): 283-291. https://doi.org/10.1107/S0021889892009944